Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Gimeracil
68
CHF
CHF 68.00
In stock
CDX-G0209-G0011 gCHF 68.00
CDX-G0209-G0055 gCHF 258.00
| Product Details | |
|---|---|
| Synonyms | 5-Chloro-4-hydroxy-2(1H)-pyridinone; 5-Chloro-2,4-dihydroxypyridine; 5-Chloro-4-hydroxy-2-pyridone; Gimestat; CDHP |
| Product Type | Chemical |
| Properties | |
| Formula |
C5H4ClNO2 |
| MW | 145.54 |
| CAS | 103766-25-2 |
| Purity Chemicals | ≥99% |
| Appearance | White to yellow crystalline powder. |
| Solubility | Soluble in DMSO (25mg/ml) or DMF (20mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ZPLQIPFOCGIIHV-UHFFFAOYSA-N |
| Smiles | ClC1=CNC(C=C1O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Gimeracil is an orally active inhibitor against dihydropyrimidine dehydrogenase (DPYD), the rate limiting enzyme for the catabolism of pyrimidines, including the chemotherapeutic drug 5-fluorouracil (5FU). It has been administered concomitantly with 5-fluorouracil in a chemotherapy regimen termed S-1 to block 5-fluorouracil degradation, thus prolonging circulating 5-fluorouracil concentrations. Furthermore, Gimeracil has been shown to inhibit homologous recombination in the repair of DNA double strand breaks, which can sensitize cancer cells to radiotherapy.
Product References
(1) T. Shirasaka, et al.; Cancer Res. 56, 2602 (1996) | (2) A.A. Adjei; Br. J. Clin. Pharmacol. 48, 265 (1999) (Review) | (3) M.D. Wyatt & D.M. Wilson; Cell Mol. Life Sci. 66, 788 (2009) | (4) M. Fukushima, et al.; Oncol. Rep. 24, 1307 (2010) | (5) K.I. Sakata, et al.; Cancer Sci. 102, 1712 (2011) | (6) K. Harada, et al.; Anticancer Res. 36, 5923 (2016)